What is the global outlook for digital therapeutics by 2030?

Across reports updated in November and early December, analysts place the global digital therapeutics market in the $25–45 billion range by 2030, anchored by cardiometabolic, respiratory, mental health, and MSK use cases. Growth assumptions depend on reimbursement depth, outcomes evidence, and integration into digital care management pathways. Vendor ecosystems featuring Omada Health, Propeller Health (ResMed), Big Health, Kaia Health, and Click Therapeutics are repeatedly cited for traction. Sources include ResearchAndMarkets, Grand View Research, and Fortune Business Insights.

Which regions are expected to contribute the most to revenue?

The United States, Europe (including the UK), and China are expected to represent the largest revenue pools by 2030. The US benefits from expanding digital care management and RTM reimbursement references; Europe draws on NICE-aligned evidence frameworks and national pilots; China scales through enterprise-grade digital health infrastructure and chronic care initiatives. India, Canada, Brazil, Saudi Arabia, and the UAE are called out for faster growth off smaller bases. See the regional estimates and sources summarized in this review.

How do reimbursement and policy changes influence DTx adoption?

Payment pathways determine how quickly DTx can be integrated into care workflows and contracted at scale. In the US, finalized 2026 policies maintain digital care management and RTM avenues, which analysts say will support payer adoption in chronic conditions. In the UK and Europe, NICE’s Evidence Standards Framework and national procurement pilots guide evaluation criteria and budgeting decisions. GCC markets leverage centralized procurement under national digitization strategies, accelerating deployments in priority disease areas.

Which therapy areas and vendors are gaining momentum right now?

Condition areas with robust outcomes evidence and clear economic cases—type 2 diabetes, hypertension, COPD/asthma, insomnia/anxiety, and MSK—are highlighted across late‑2025 updates. Notable vendors include Omada Health (cardiometabolic), Propeller Health/ResMed (respiratory), Big Health (sleep and mental health), Kaia Health (MSK), Click Therapeutics (psychiatry/neurology), and Akili Interactive (ADHD). Earnings commentary and analyst landscapes point to employer and payer demand intensifying into 2026 renewals.

What should procurement teams prioritize for 2026–2027 contracts?

Buyers should stress-test claims against peer‑reviewed evidence and real‑world outcomes, require EMR/device integration roadmaps, and align contracts with available billing or reimbursement codes. Outcomes‑based arrangements are gaining traction in employer and payer channels. Focus on vendors with demonstrated reductions in A1c, hospitalization risk, or validated symptom scales, plus clear data governance. Shortlists often include Omada Health, Big Health, Kaia Health, and Click Therapeutics, which are frequently profiled in late‑2025 analyst updates.

A Review of Digital Therapeutics Market Size Reports 2025-2030 for UK, Europe, US, Canada, UAE, Saudi Arabia, India, Brazil and China

New analyses released since late October outline how digital therapeutics could scale to multi‑billion dollar markets by 2030 across the US, Europe, China and key emerging regions. We synthesize the latest forecasts, regulatory signals, and earnings clues to map out demand, reimbursement, and vendor momentum through 2025–2030.

Published: December 7, 2025 By James Park Category: Health Tech

A Review of Digital Therapeutics Market Size Reports 2025-2030 for UK, Europe, US, Canada, UAE, Saudi Arabia, India, Brazil and China

Executive Summary

New reports published in late October–early December estimate the global digital therapeutics (DTx) market will reach roughly $25–45 billion by 2030, with regional breakouts highlighting the US, Europe and China as the largest demand centers (ResearchAndMarkets; Grand View Research).
Country-level 2030 ranges tracked in this review: US $10–15B, Europe $8–12B, China $3–5B, India $1.5–2.5B, UK $1.5–2.5B, Canada $1–1.5B, Brazil $0.8–1.2B, Saudi Arabia $0.4–0.7B, UAE $0.3–0.6B (compilations from Q4 analyst notes and updated vendor landscapes; sources cited below).
Regulatory and reimbursement signals in the last 45 days include US payment policy updates touching digital care management and RTM that are expected to support DTx uptake into 2026 (CMS), alongside active European evidence and procurement frameworks (NICE ESF).
Earnings commentary from connected-respiratory and digital care platforms points to payer appetite for condition-specific software interventions as employers and plans seek outcomes-based models (ResMed IR; Teladoc Health IR).

What the Latest Reports Say About 2025–2030 DTx Demand

Across market studies released since late October, analysts converge on a mid‑teens global CAGR for digital therapeutics through 2030, driven by cardiometabolic, respiratory, mental health, and musculoskeletal use cases. Syntheses published in November indicate worldwide revenue potential in the $25–45 billion range by 2030, with stronger reimbursement penetration boosting the top end of forecasts (ResearchAndMarkets; Fortune Business Insights). These ranges reflect both prescription DTx and regulated software interventions deployed via payer, employer, and provider channels.

Vendor landscapes in these reports consistently cite therapy-area specialists such as Omada Health, Propeller Health (part of ResMed), Big Health, Kaia Health, Sidekick Health, Click Therapeutics, and Akili Interactive...

Read the full article at AI BUSINESS 2.0 NEWS